$NVO

AI Analysis

Generated on May 13, 2026

AI Score
78/ 100
Buy$NVO

Novo Nordisk A/S

$NVONYSEHealthcareMega-Cap

Novo Nordisk is a global healthcare company specializing in diabetes care and obesity treatment, maker of blockbuster GLP-1 drugs Ozempic, Wegovy, and Rybelsus.

Market Cap
$480.0B
Revenue (TTM)
$42.6B
+26.0%
Net Income (TTM)
$15.8B
+28.0%
EPS (TTM)
$3.52
P/E Ratio
32.0
Dividend Yield
1.2%
52-Week Range
$80-$148
Beta
0.82
Dimension Scores
Fundamental
82
Technical
72
Sentiment
76
Risk / Reward
74
Momentum
78
FundTechSentRiskMome
Financial Health
Profitability
87strong
Growth
81strong
Liquidity
82strong
Solvency
84strong
Efficiency
80strong

Valuation, technical analysis, investment thesis, risk assessment and more for $NVO

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.